All In Biotech

Drug Trial Radar · NCT05669950

A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia

A Multi-site, Open-label, Sequential-group, Multiple-dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia

Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Dec 19, 2022

Primary completion

Sep 30, 2026

Study completion Dec 31, 2027

Sponsor

Lead sponsor
H. Lundbeck A/SIndustry
Sponsor type
Industry
First posted
Jan 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will evaluate the effects of different doses of Lu AG13909 in adult participants with congenital adrenal hyperplasia, also called CAH. CAH is a rare genetic disorder that affects a person's ability to produce certain hormones. The main goals of this trial are to learn about the safety and tolerability of Lu AG13909, how Lu AG13909 behaves in the body, and how the body responds to Lu AG13909.

Conditions

  • Congenital Adrenal Hyperplasia

Interventions

  • Lu AG13909Drug

    Solution for infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts A and B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to Day 161
  2. Parts A and B: Number of Participants With Anti-Drug Antibodies (ADAs)Time frame: Day 1 up to Day 161
  3. Parts A and B: Cmax: Maximum Observed Serum Concentration of Lu AG13909Time frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161
  4. Parts A and B: Tmax: Nominal Time Corresponding to the Occurrence of CmaxTime frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161
  5. Parts A and B: Ctrough: Minimum Observed Serum Concentration of Lu AG13909Time frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161
  6. Parts A and B: t½: Apparent Elimination Half-life of Lu AG13909Time frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161
  7. Parts A and B: AUC0-infinity: Area under the plasma concentration curve of x from zero to infinity of Lu AG13909Time frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161
  8. Parts A and B: CL: Apparent Total Serum Clearance of Lu AG13909Time frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161
  9. Parts A and B: Vz: Volume of Distribution During the Terminal Elimination Phase After IV Administration of Lu AG13909Time frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161
  10. Parts A and B: Change From Baseline After Each Dose of Lu AG13909 in Blood Concentrations of 17-hydroxyprogesterone (17-OHP) and Androstenedione (A4)Time frame: Baseline up to Day 85
  11. Parts A and B: AUC0-tau: Area under the curve over a dosing intervalTime frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161
  12. Part C: Morning Concentration of A4 in Blood <Upper Limit of Normal (ULN)Time frame: Day 169

Locations

17 sites in 9 countries. Site status is shown where the registry gives one.

  • University Hospital-University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • Chu Angers

    Angers, France · Recruiting

  • CHU de Lille

    Lille, France · Recruiting

  • GH Pitié-Salpêtrière

    Paris, France · Recruiting

  • CHRU Strasbourg

    Strasbourg, France · Recruiting

  • David Metreveli Medical Centre, Tbilisi

    Tbilisi, Georgia · Recruiting

  • Beaumont Hospital Royal College of Surgeons in Ireland (RCSI), Dublin

    Dublin, Ireland · Recruiting

  • Azienda Ospedaliero Universitaria di Bologna

    Bologna, Italy · Recruiting

  • Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma

    Roma, Italy · Recruiting

  • Centrum Nowoczesnych Terapii, Dobry Lekarz

    Dobry Lekarz, Poland · Recruiting

  • Sahlgrenska University Hospital

    Gothenburg, Sweden · Recruiting

  • Karolinska University Hospital

    Stockholm, Sweden · Recruiting

  • NIHR/Wellcome Trust Clinical Research Facility

    Birmingham, United Kingdom · Recruiting

  • Cambridge Clinical Research Centre

    Cambridge, United Kingdom · Recruiting

  • NIHR Clinical Research Facility

    London, United Kingdom · Recruiting

  • University College London Hospital - NIHR

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.